CN105831733A - 一种茶油降脂胶囊 - Google Patents
一种茶油降脂胶囊 Download PDFInfo
- Publication number
- CN105831733A CN105831733A CN201610172237.7A CN201610172237A CN105831733A CN 105831733 A CN105831733 A CN 105831733A CN 201610172237 A CN201610172237 A CN 201610172237A CN 105831733 A CN105831733 A CN 105831733A
- Authority
- CN
- China
- Prior art keywords
- powder
- liquid
- semen
- weight
- semen glycines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 42
- 150000002632 lipids Chemical class 0.000 title abstract description 11
- 239000010495 camellia oil Substances 0.000 title abstract 6
- 239000007788 liquid Substances 0.000 claims abstract description 78
- 239000000843 powder Substances 0.000 claims abstract description 72
- 235000013372 meat Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 15
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 9
- 235000006533 astragalus Nutrition 0.000 claims abstract description 9
- 239000000787 lecithin Substances 0.000 claims abstract description 9
- 235000010445 lecithin Nutrition 0.000 claims abstract description 9
- 229940067606 lecithin Drugs 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 241000237502 Ostreidae Species 0.000 claims abstract description 8
- 235000020636 oyster Nutrition 0.000 claims abstract description 8
- 238000004806 packaging method and process Methods 0.000 claims abstract description 4
- 210000000582 semen Anatomy 0.000 claims description 117
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 107
- 150000002333 glycines Chemical class 0.000 claims description 64
- 210000004369 blood Anatomy 0.000 claims description 47
- 239000008280 blood Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 239000009636 Huang Qi Substances 0.000 claims description 44
- 239000002893 slag Substances 0.000 claims description 40
- 241000972773 Aulopiformes Species 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 33
- 235000019515 salmon Nutrition 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000006286 aqueous extract Substances 0.000 claims description 11
- 241001107116 Castanospermum australe Species 0.000 claims description 10
- 241000208688 Eucommia Species 0.000 claims description 10
- 235000021279 black bean Nutrition 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 239000000052 vinegar Substances 0.000 claims description 9
- 235000021419 vinegar Nutrition 0.000 claims description 9
- 241001061264 Astragalus Species 0.000 claims description 8
- 210000004233 talus Anatomy 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 210000001835 viscera Anatomy 0.000 claims description 5
- 108010059892 Cellulase Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 229940106157 cellulase Drugs 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000001223 reverse osmosis Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 238000000703 high-speed centrifugation Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 238000002386 leaching Methods 0.000 claims 1
- 238000005374 membrane filtration Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 44
- 235000012000 cholesterol Nutrition 0.000 abstract description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 11
- 244000269722 Thea sinensis Species 0.000 abstract description 10
- 240000008042 Zea mays Species 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 5
- 244000068988 Glycine max Species 0.000 abstract description 4
- 235000010469 Glycine max Nutrition 0.000 abstract description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract description 3
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract description 2
- 235000007244 Zea mays Nutrition 0.000 abstract description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract description 2
- 235000005822 corn Nutrition 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 241000277331 Salmonidae Species 0.000 abstract 1
- 229940089639 cornsilk Drugs 0.000 abstract 1
- 244000237330 gutta percha tree Species 0.000 abstract 1
- 239000001231 zea mays silk Substances 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 32
- 230000000694 effects Effects 0.000 description 14
- 235000013616 tea Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- -1 beta glucan glycosides Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 1
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000526900 Camellia oleifera Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 241000548230 Crassostrea angulata Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000277329 Oncorhynchus keta Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940092385 radish extract Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开的一种茶油降脂胶囊,涉及生物医药技术领域,是由以下重量份的原料制备而成:茶油25‑30、玉米液5‑10、玉米须粉1‑3、黄豆液10‑15、黑豆粉2‑4、卵磷脂0.5‑1.75、山药粉5‑10、鲑鱼粉2‑5、杜仲叶粉4‑8、黄芪液4‑8、茶叶液5‑12、牡蛎肉液3‑8;其制备过程如下:⑴、初混合;⑵、复混合;⑶、包装。具有能够降低人体胆固醇和甘油三酯等特点,适用于预防和治疗高胆固醇血症、高甘油三酯血症或两者兼有的高脂血症。
Description
技术领域
本发明涉及生物医药技术领域,特别是一种能够降低血脂的茶油降脂胶囊。
背景技术
高脂血症是由于脂肪代谢或运转异常,使血浆中的一种或多种脂质高于正常值,脂质不溶或微溶于水必须与蛋白质结合以脂蛋白形式存在,因此,高脂血症常为高脂蛋白血症(hyperlipoproteinemia),表现为高胆固醇血症、高甘油三酯血症或两者兼有。
随着社会的发展,人们的生活水平越来越高,随之而来的却是肥胖的人越来越多,引起高脂血症,进而形成冠状动脉粥样硬化性心脏病等所谓的“富贵病”。
目前,降低血脂的方式除了控制饮食和适度的运动以外,药物主要有:他汀类药物、贝特类药物、胆酸螯合剂、烟酸等。
中国专利(专利申请号为200610076706.1)公开的“一种降低血液胆固醇及甘油三酯的保健剂”,其成分包括:绿茶提取物7~10份,红茶提取物3~5份,红酵母8~10份;进一步的技术方案中还包括:白萝卜提取物3~6份,烟酸0.1~0.5份,灵芝提取物0.1~0.5份,叶酸≤0.1份。另一中国专利(专利申请号为201210200750.4)公开的“一种能降低胆固醇的茶及其制备方法”,所述茶由泽泻提取物、葡萄、苹果皮、刺蒺藜、绿茶与辅料果胶酶和苯甲酸钠制成。还有中国专利(专利申请号为200810141482.7)公开的“参降脂胶囊”,是由杜仲、丹参、红花、何首乌、山楂、黄芪、胶股蓝、银杏叶、山药进行组合制成的。
发明内容
本发明的目的在于提供一种能够降低人体胆固醇和甘油三酯的保健食品。
为实现上述目的,本发明所采取的技术措施是发明一种茶油降脂胶囊,是由以下重量份的原料制备而成:
其制备过程如下:
⑴、初混合:先将茶油、玉米液、卵磷脂、牡蛎肉液一起混合均匀,得混合液一;再将黄豆液、黄芪液、茶叶液一起混匀,得混合液二;再将混合液一缓慢加入到混合液二中,边加边搅,然后在频率为500-700Hz的振荡器中处理5-8h,得总混合液;再将总混合液经喷雾干燥,得干粉一,备用;
⑵、复混合:将干粉一与山药粉、玉米须粉、杜仲叶粉、鲑鱼粉、黑豆粉一起混匀,经均质机处理,得均质细粉,备用;
⑶、包装:在洁净室中,将胶囊壳和均质细粉由胶囊填充机,经填装、抛光、包装后,即得茶油降脂胶囊。
所述的玉米液,是将玉米(鲜)经压榨处理,收集滤出的玉米液;也可以是将玉米(鲜)在0-8℃下经冷压榨处理,收集滤出的玉米液。
所述的玉米须粉,是将玉米须直接粉碎成300目以上的细粉;也可以是按以下方法制备而成:将玉米须洗净,加入到1-3倍重量、体积浓度为30-45%的食醋水溶液中,在40-50℃下浸泡10-16h,过滤;再将经过浸泡的玉米须用清水洗涤2-4次,然后转移到烘箱中,在40-50℃下烘干至水分含量≤6%,得干玉米须;再将干玉米须粉碎成300目以上的细粉,得玉米须粉。
所述的黄豆液,是将黄豆用1-3倍重量、45-60℃的温水密封浸泡至膨大至1/4-1/2后,磨浆,再用200-300目筛滤去黄豆渣后所得;也可以是按以下方法制备而成:将黄豆洗净,用1-3倍重量、45-60℃的温水密封浸泡至膨大至1/4-1/2,过滤;再将经过浸泡的黄豆经挤压机处理,收集滤出的黄豆水液和黄豆渣;再将黄豆渣投入2-4倍重量、体积浓度为60-70%的乙醇中,常温浸泡10-15h,过滤,收集黄豆渣醇提液;将黄豆渣醇提液与同等重量、浓度为4-8%的硫酸盐(为硫酸钠、硫酸钙、硫酸氢钠中的一种)溶液混合,得黄豆渣醇提混合液;再将黄豆渣醇提混合液按2-4℃/min的升温速度加热至40-50℃,搅匀,过S-330型大孔树脂,控制流速为15-28L/h;再用与上述黄豆渣醇提混合液同等重量、体积浓度为65-85%的食用乙醇洗脱,流速为40-50L/h,收集黄豆渣醇洗脱液;将黄豆渣醇洗脱液用蒸馏水稀释至醇度(即:乙醇的体积浓度)为30-45%,再在压力为1.2-1.75MPa的条件下,经反渗透膜(膜的滤孔孔径为2-10nm)过滤,收集黄豆渣醇洗脱过滤液;将黄豆渣醇洗脱过滤液在压力为10-16KPa、温度为55-70℃下浓缩至原体积的20-35%,得黄豆渣浓缩液;将黄豆渣浓缩液和上述收集的黄豆水液合并,搅匀,即得黄豆液。
所述的黑豆粉,是将黑豆洗净,干燥后粉碎成300目以上的黑豆粉;也可以是按以下方法制备而成:将黑豆洗净,分离成黑豆皮和黑豆肉;将黑豆肉用1-3倍重量、45-55℃的清水密封浸泡15-30h,再将经过浸泡的黑豆肉在30-45℃下经挤压机反复处理2-3次,收集滤出的黑豆肉液,再经喷雾干燥成粉末,得黑豆肉干粉;将黑豆皮干燥后粉碎成300目以上的黑豆皮粉;再将黑豆肉干粉和黑豆皮粉混合,即得黑豆粉。
所述的山药粉,是将山药(鲜)剥去外表皮,洗净,烘干至水份≤8%,再粉碎成80目以上的山药粉;也可以是按以下方法制备而成:将山药剥去外表皮,洗净,然后,整根放入沸水中,煮至7-8成熟,捞出;将煮过的山药切成片状(厚度为1-1.5cm),与占原山药重量1-2%的蛋白酶(可为木瓜蛋白酶或其它蛋白酶)、0.5-1.5%的纤维素酶(可为β-葡聚糖苷酶或其它纤维素酶)一起投入打浆机中处理成20-60目的浆料,在25-35℃下密封处理16-24h,过滤,收集余下浆渣;将浆渣用同等重量、4-10℃的清水浸泡20-30min,过滤;将经过浸泡浆渣在60-70℃下烘干至水份≤8%,再粉碎成80目以上的山药粉。
所述的杜仲叶粉,是将将杜仲叶洗净,烘干至水份≤8%,再粉碎成80目以上的杜仲叶粉;也可以是按以下方法制备而成:将杜仲叶洗净,投入2-4倍重量、体积浓度为70-85%的乙醇中,常温浸泡5-10h,过滤,收集杜仲叶醇提液;将杜仲叶醇提液用清水稀释至醇度(即:乙醇的体积浓度)为30-35%,再用浓度为5-10%的盐酸调节pH值为5-6,得杜仲叶醇提处理液;将杜仲叶醇提处理液过由硅胶:硅藻土=4-6:1的重量比例混合制成的混合柱,流速为10-18L/h,再用由乙酸乙酯与石油醚混合组成的混合溶剂洗脱,收集乙酸乙酯:石油醚=2:0.5的洗脱馏段的杜仲叶洗脱液;将杜仲叶洗脱液在压力为8-12KPa、温度为45-60℃下浓缩至原杜仲叶洗脱液体积的1/2,得杜仲叶浓缩液;将杜仲叶浓缩液用45-60℃的温水搅拌稀释2-3倍后,转移至冷库中,静放10-15h,过滤,收集杜仲叶水液;将杜仲叶水液经喷雾干燥,得杜仲叶粉。
所述的黄芪液,是将黄芪,洗净,加入到1-3倍重量的清水中,煮至原体积的30-40%时,滤去黄芪渣后所得;也可以是按以下方法制备而成:将黄芪,洗净、晒干,切成黄芪薄片(厚1.5-2.0mm);将黄芪薄片加入到1-3倍重量、体积浓度为35-45%的食用乙醇溶液,在40-55℃下浸泡5-8h,过滤,收集黄芪醇提液;再向黄芪薄片中加入同等重量、体积浓度为60-75%的食用乙醇溶液,常温下浸泡1-3h,过滤,收集二次黄芪醇提液;将黄芪醇提液与二次黄芪醇提液合并成黄芪醇提混合液,将黄芪醇提混合液在压力为5-10KPa、温度为50-60℃下浓缩至无醇,得无醇黄芪浓缩液;将无醇黄芪浓缩液转移至压力为2-5KPa、温度为45-55℃条件下浓缩至原黄芪薄片重量的30-45%,得黄芪浓缩液;向黄芪浓缩液中加入占黄芪浓缩液重量10-25%的麦芽糖,搅匀,然后转移至0-10℃的冷库中,静放5-10h,过滤,收集黄芪液。
所述的茶叶液,是将茶叶(鲜)加入到1-3倍重量的清水中,煮至原体积的30-40%时,滤去茶叶渣后所得;也可以是按以下方法制备而成:将茶叶洗净,加入到2-5倍重量、pH值为6.5-7的去离子水,煮沸提取20-40min,过滤,收集茶叶水提液;待茶叶水提液冷却到10℃以下时,经10000-15000r/min的高速离心机离心,收集茶叶离心液;将茶叶离心液在压力为5-10KPa、温度为60-70℃下浓缩至原体积的20-35%,得茶叶液。
所述的鲑鱼粉,是将鲑鱼除去内脏和鳞片,洗净,烘干至水份≤8%,再粉碎成80目以上的鲑鱼粉;也可以是按以下方法制备而成:将鲑鱼除去内脏和鳞片,洗净,切成鲑鱼薄片(2-5mm厚),浸泡在纯食用醋中,时间为5-8min,捞出,沥干;再将经过浸泡的鲑鱼薄片用2-4倍重量的去离子水煮沸提取1-2h,过滤,收集鲑鱼水提液;再向鲑鱼水提液中加入占鲑鱼水提液重量5-10%的果糖、5-10%的麦芽糊精、0.5-1.5%的氯化钠,搅匀,经喷雾干燥,得鲑鱼粉。
所述的牡蛎液,是将牡蛎肉去除内脏,洗净,在0-10℃下经冷压榨处理,收集滤出的牡蛎液;也可以是按以下方法制备而成:将牡蛎肉去除内脏,洗净,放入纯食用醋中浸泡40-65min,捞出,在35-45℃下自然放置6-10h;再将牡蛎肉在0-10℃下经冷压榨处理,收集滤出的牡蛎液。
本发明的茶油降脂胶囊,其主要原料包括油茶、玉米、玉米须、黄豆、黑豆、卵磷脂、山药、鲑鱼、杜仲叶、黄芪、茶叶和牡蛎肉。
油茶(Camellia oleifera Abel)属山茶科,是我国主要的和特有的木本油料树。油茶的综合利用价值很高,含有丰富的不饱和脂肪酸、单不饱和脂肪酸、维生素E、角鲨烯、茶多酚等生物活性物质。单不饱和脂肪酸能提高血液抗氧化能力,降低胆固醇,防止心脑血管疾病的发生,还能降低诸如胰岛素拮抗性糖尿病之类因代谢失调而引起的疾病的出现机率,不饱和脂肪酸具有不聚脂”特性,不仅自身不在内脏及皮下沉积,而且能够阻止脂肪沉积,可以避免发胖,在医学上,茶油用于辅助治疗肥胖症,是一种“吃油不怕胖”的健康食用油。
玉米(Zea mays)亦称玉蜀黍、包谷、苞米、棒子,是一年生禾本科草本植物,是重要的粮食作物和重要的饲料来源,也是全世界总产量最高的粮食作物。玉米胚中的玉米油含有大量不饱和脂肪酸,其中亚油酸占60%,可清除血液中有害的胆固醇,防止动脉粥样硬化。
玉米须利尿消肿,平肝利胆。用于急、慢性肾炎,水肿,急、慢性肝炎,高血压,糖尿病,慢性鼻窦炎,尿路结石,胆道结石,小便不利、湿热黄胆等症。
黄豆(即:大豆)[Glycine max(L.)Merr],黄豆中的卵磷脂可除掉附在血管壁上的胆固醇,防止血管硬化,预防心血管疾病,保护心脏。大豆中的卵磷脂还具有防止肝脏内积存过多脂肪的作用,从而有效地防治因肥胖而引起的脂肪肝。同时,大豆中的植物固醇有降低血液胆固醇的作用。它在肠道内可与胆固醇竞争,减少胆固醇吸收,在降低高脂血症患者血液中的“坏胆固醇”的同时,不影响血液中的“好胆固醇”,有很好的降脂效果。
黑豆(即:黑色的大豆)[Glycine max(L.)Merr],黑豆基本不含胆固醇,只含植物固醇,而植物固醇不被人体吸收利用,又有抑制人体吸收胆固醇、降低胆固醇在血液中含量的作用。同时,黑豆皮中含有花青素,能有效防止脂肪进入小肠后被人体吸收,同时令脂肪顺利排出体外,不易造成积聚。
卵磷脂(Lecithin),具有乳化、分解油脂的作用,可增进血液循环,改善血清脂质,清除过氧化物,使血液中胆固醇及中性脂肪含量降低,减少脂肪在血管内壁的滞留时间,促进粥样硬化斑的消散,防止由胆固醇引起的血管内膜损伤。
山药(Dioscorea opposita),新鲜块茎中含有的多糖蛋白成分的粘液质、消化酵素等,可预防心血管脂肪沉积,有助于胃肠的消化和吸收。
鲑鱼(Oncorhynchus keta)(又名三文鱼),鲑鱼中含有丰富的不饱和脂肪酸,能有效降低血脂和血胆固醇,防治心血管疾病。
杜仲叶(Eucommia folium),杜仲叶提取物能较好地促进肌体中胶原蛋白的新陈代谢,增强细胞的活力,其抗衰老作用是维生素E的4倍以上,对肌体的体液免疫和细胞的免疫也有明显的增强作用。此外,杜仲叶还有降血脂、减少中性脂肪形成的作用。
黄芪(Leguminosae),具有补气固表,利尿托毒,排脓,敛疮生肌的功效。用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴。黄芪补气固表功效相关的药理作用为增强机体免疫功能、增强造血功能。改善物质代谢、增强性腺功能、抗应激、延缓衰老等作用。黄芪还具有强心、调节血压、抗病毒性心肌炎、保肝、抗溃疡等作用。
茶叶(a tea leaf),茶叶中所含的儿茶素类(俗称茶单宁)具抗氧化、抗突然异变、抗肿瘤、降低血液中胆固醇及低低密度酯蛋白含量、抑制血压上升、抑制血小板凝集、抗菌、抗产物过敏等功效。
牡蛎肉(ostrea gigas thunberg),清肺补心,滋阴养血。
由上述诸多原料制备的茶油降脂胶囊,含有多种降脂物质和对人体有益的活性物质,因而,能够有效降低血浆中的胆固醇及甘油三酯,防止心脑血管疾病的发生。
下面的表1是本发明的茶油降脂胶囊的有效成份检测数据:
表1本发明的的茶油降脂胶囊的有效成份检测表(100g的含量)
从上表数据可以看出,本发明的茶油降脂胶囊,不仅含有丰富的单不饱和脂肪酸和不饱和脂肪酸,还含有较多的花青素、儿茶素等有益物质。
本发明的茶油降脂胶囊,曾对60例高胆固醇血症或混合性高脂血症患者进行过降脂试验:
1、试验资料:
⑴、诊断标准:参照《中药新药治疗高血脂症的临床研究指导原则》和1997年全国血脂异常防治对策研究组编写的《血脂异常防治建议》,由县级以上医院检验、符合以下情况之一者,即可确诊:①胆固醇(TC)≥5.7mmol/L;②甘油三脂(TG)≥1.7mmol/L,低密度脂蛋白(LDL-C)≥3.6mmol/L,高密度脂蛋白(HDL-C)≤1.0mmol/L。
⑵、一般资料:符合上述诊断标准的60例患者,随机分成试验组40例,对照组20例;其中:试验组中,男25例、女15例,年龄35-60岁,平均年龄46岁,患病时间1个月-1年,胆固醇(TC)偏高22例,甘油三脂(TG)偏高18例;对照组中,男12例、女8例,年龄35-55岁,平均年龄43岁,患病时间1个月-1年,胆固醇(TC)偏高15例,甘油三脂(TG)偏高5例。
2、试验方法:
⑴、试验组服用由以下重量份的原料制备而成的茶油降脂胶囊(即:后面的实施例3):
⑵、试验组服用方法:每天早中晚三次,每次服用0.6克(每粒胶囊含有有效成份0.3克,即:2粒),30天为一个疗程,60天后进行统计。
⑶、试验组服用时间注意事项:在饭后1.5h服用或饭前1h服用。
⑷、对照组服用常规的降脂药物(如:他汀类药物、贝特类药物、胆酸螯合剂、烟酸等)。
3、疗效判定标准:
参照《中药新药治疗高血脂症的临床研究指导原则》拟定。
⑴、显效:治疗后血脂检测达到以下任何1项者,即:TC下降≥20%,或TG下降≥40%,或HDL-C上升≥0.26mmol/L,或HDL-C/LDL-C≥20%;
⑵、有效:治疗后血脂检测达到以下任何1项者,即:TC下降<20%,或TG下降≥20%<40%,或HDL-C上升≥0.104mmol/L<0.26mmol/L,或HDL-C/LDL-C≥10%<20%;
⑶、无效:治疗后血脂检测无明显改善或改善达不到有效标准。
总有效率按显效加有效统计。
4、治疗结果:
⑴、试验组:共40例,其中:显效22例,有效15例,无效3例,总有效率92.5%;
⑵、对照组:共20例,其中:显效11例,有效5例,无效4例,总有效率80%。
从上面的治疗结果数据可以看出,本发明的茶油降脂胶囊有较好的降脂效果。
具体实施方式
以下结合实施例,对本发明作进一步的说明。下面的说明是以例举的方式,但本发明的保护范围并不局限于此。
实施例1:
本实施例的茶油降脂胶囊,其制备过程如下:
一、原料预处理:
1、玉米液制备:将玉米(鲜)在4℃下经冷压榨处理,收集滤出的玉米液,备用;
2、玉米须粉制备:将玉米须洗净,加入到2倍重量、体积浓度为40%的食醋水溶液中,在45℃下浸泡12h,过滤;再将经过浸泡的玉米须用清水洗涤3次,然后转移到烘箱中,在45℃下烘干至水分含量≤6%,得干玉米须;再将干玉米须粉碎成300目以上的细粉,得玉米须粉,备用;
3、黄豆液制备:将黄豆洗净,用2倍重量、50℃的温水密封浸泡至膨大至1/3,过滤;再将经过浸泡的黄豆经挤压机处理,收集滤出的黄豆水液和黄豆渣;再将黄豆渣投入3倍重量、体积浓度为65%的乙醇中,常温浸泡12h,过滤,收集黄豆渣醇提液;将黄豆渣醇提液与同等重量、重量浓度为6%的硫酸钠溶液混合,得黄豆渣醇提混合液;再将黄豆渣醇提混合液按3℃/min的升温速度加热至45℃,搅匀,过S-330型大孔树脂,控制流速为22L/h;再用与上述黄豆渣醇提混合液同等重量、体积浓度为75%的食用乙醇洗脱,流速为45L/h,收集黄豆渣醇洗脱液;将黄豆渣醇洗脱液用蒸馏水稀释至醇度(即:乙醇的体积浓度)为35%,再在压力为1.5MPa的条件下,经反渗透膜(膜的滤孔孔径为2-10nm)过滤,收集黄豆渣醇洗脱过滤液;将黄豆渣醇洗脱过滤液在压力为12KPa、温度为60℃下浓缩至原体积的30%,得黄豆渣浓缩液;将黄豆渣浓缩液和上述收集的黄豆水液合并,搅匀,即得黄豆液,备用;
4、黑豆粉制备:将黑豆洗净,分离成黑豆皮和黑豆肉;将黑豆肉用2倍重量、50℃的清水密封浸泡25h,再将经过浸泡的黑豆肉在35℃下经挤压机反复处理2-3次,收集滤出的黑豆肉液,再经喷雾干燥成粉末,得黑豆肉干粉;将黑豆皮干燥后粉碎成300目以上的黑豆皮粉;再将黑豆肉干粉和黑豆皮粉混合,即得黑豆粉。
5、山药粉制备:将山药剥去外表皮,洗净,然后,整根放入沸水中,煮至7-8成熟,捞出;将煮过的山药切成片状(厚度为1.2cm),与占原山药重量1.5%的蛋白酶(本例采用木瓜蛋白酶)、1%的纤维素酶(本例采用β-葡聚糖苷酶)一起投入打浆机中处理成40目的浆料,在30℃下密封处理20h,过滤,收集余下浆渣;将浆渣用同等重量、8℃的清水浸泡25min,过滤;将经过浸泡浆渣在65℃下烘干至水份≤8%,再粉碎成80目以上的山药粉,备用;
6、杜仲叶粉制备:将杜仲叶洗净,投入3倍重量、体积浓度为80%的乙醇中,常温浸泡8h,过滤,收集杜仲叶醇提液;将杜仲叶醇提液用清水稀释至醇度(即:乙醇的体积浓度)为32%,再用浓度为8%的盐酸调节pH值为5.5,得杜仲叶醇提处理液;将杜仲叶醇提处理液过由硅胶:硅藻土=5:1的重量比例混合制成的混合柱,流速为15L/h,再用由乙酸乙酯与石油醚混合组成的混合溶剂洗脱,收集乙酸乙酯:石油醚=2:0.5的洗脱馏段的杜仲叶洗脱液;将杜仲叶洗脱液在压力为10KPa、温度为50℃下浓缩至原杜仲叶洗脱液体积的1/2,得杜仲叶浓缩液;将杜仲叶浓缩液用50℃的温水搅拌稀释2.5倍后,转移至冷库中,静放12h,过滤,收集杜仲叶水液;将杜仲叶水液经喷雾干燥,得杜仲叶粉,备用;
7、黄芪液制备:将黄芪,洗净、晒干,切成厚度为2mm的黄芪薄片;将黄芪薄片加入到2倍重量、体积浓度为40%的食用乙醇溶液,在45℃下浸泡6h,过滤,收集黄芪醇提液;再向黄芪薄片中加入同等重量、体积浓度为65%的食用乙醇溶液,常温下浸泡2h,过滤,收集二次黄芪醇提液;将黄芪醇提液与二次黄芪醇提液合并成黄芪醇提混合液,将黄芪醇提混合液在压力为8KPa、温度为55℃下浓缩至无醇,得无醇黄芪浓缩液;将无醇黄芪浓缩液转移至压力为4KPa、温度为50℃条件下浓缩至原黄芪薄片重量的35%,得黄芪浓缩液;向黄芪浓缩液中加入占黄芪浓缩液重量20%的麦芽糖,搅匀,然后转移至4℃的冷库中,静放8h,过滤,收集黄芪液,备用;
8、茶叶液制备:将茶叶洗净,加入到4倍重量、pH值为6.5的去离子水,煮沸提取30min,过滤,收集茶叶水提液;待茶叶水提液冷却到10℃以下时,经12000r/min的高速离心机离心,收集茶叶离心液;将茶叶离心液在压力为8KPa、温度为65℃下浓缩至原体积的30%,得茶叶液,备用;
9、鲑鱼粉制备:将鲑鱼除去内脏和鳞片,洗净,切成厚度为3m m的鲑鱼薄片,浸泡在纯食用醋中,时间为6min,捞出,沥干;再将经过浸泡的鲑鱼薄片用3倍重量的去离子水煮沸提取1.5h,过滤,收集鲑鱼水提液;再向鲑鱼水提液中加入占鲑鱼水提液重量8%的果糖、8%的麦芽糊精、1%的氯化钠,搅匀,经喷雾干燥,得鲑鱼粉,备用;
10、牡蛎液制备:将牡蛎肉去除内脏,洗净,放入纯食用醋中浸泡55min,捞出,在40℃下自然放置8h;再将牡蛎肉在4℃下经冷压榨处理,收集滤出的牡蛎液,备用。
二、备料:
按重量份分别取下列原料:
三、制备过程:
⑴、初混合:先将茶油、玉米液、卵磷脂、牡蛎肉液一起混合均匀,得混合液一;再将黄豆液、黄芪液、茶叶液一起混匀,得混合液二;再将混合液一缓慢加入到混合液二中,边加边搅,然后在频率为600Hz的振荡器中处理6h,得总混合液;再将总混合液经喷雾干燥,得干粉一,备用;
⑵、复混合:将干粉一与山药粉、玉米须粉、杜仲叶粉、鲑鱼粉、黑豆粉一起混匀,经均质机处理,得均质细粉,备用;
⑶、包装:在洁净室中,将胶囊壳和均质细粉由胶囊填充机,经填装、抛光、包装后,即得茶油降脂胶囊。每粒茶油降脂胶囊专,含有有效成份0.3克。
实施例2:
本实施例的茶油降脂胶囊,其制备过程如下:
一、原料预处理:
与实施例1相同;
二、备料:
按重量份分别取下列原料:
三、制备过程:
与实施例1相同。
实施例3:
本实施例的茶油降脂胶囊,其制备过程如下:
一、原料预处理:
与实施例1相同;
二、备料:
按重量份分别取下列原料:
三、制备过程:
与实施例1相同。
本发明的茶油降脂胶囊,适用于预防和治疗高胆固醇血症、高甘油三酯血症或两者兼有的高脂血症。
Claims (10)
1.一种茶油降脂胶囊,其特征在于是由以下重量份的原料制备而成:
其制备过程如下:
⑴、初混合:先将茶油、玉米液、卵磷脂、牡蛎肉液一起混合均匀,得混合液一;再将黄豆液、黄芪液、茶叶液一起混匀,得混合液二;再将混合液一缓慢加入到混合液二中,边加边搅,然后在频率为500-700Hz的振荡器中处理5-8h,得总混合液;再将总混合液经喷雾干燥,得干粉一,备用;
⑵、复混合:将干粉一与山药粉、玉米须粉、杜仲叶粉、鲑鱼粉、黑豆粉一起混匀,经均质机处理,得均质细粉,备用;
⑶、包装:在洁净室中,将胶囊壳和均质细粉由胶囊填充机,经填装、抛光、包装后,即得茶油降脂胶囊。
2.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的玉米须粉是按以下方法制备而成:将玉米须洗净,加入到1-3倍重量、体积浓度为30-45%的食醋水溶液中,在40-50℃下浸泡10-16h,过滤;再将经过浸泡的玉米须用清水洗涤2-4次,然后转移到烘箱中,在40-50℃下烘干至水分含量≤6%,得干玉米须;再将干玉米须粉碎成300目以上的细粉,得玉米须粉。
3.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的黄豆液是按以下方法制备而成:将黄豆洗净,用1-3倍重量、45-60℃的温水密封浸泡至膨大至1/4-1/2,过滤;再将经过浸泡的黄豆经挤压机处理,收集滤出的黄豆水液和黄豆渣;再将黄豆渣投入2-4倍重量、体积浓度为60-70%的乙醇中,常温浸泡10-15h,过滤,收集黄豆渣醇提液;将黄豆渣醇提液与同等重量、浓度为4-8%的硫酸盐溶液混合,得黄豆渣醇提混合液;再将黄豆渣醇提混合液按2-4℃/min的升温速度加热至40-50℃,搅匀,过S-330型大孔树脂,控制流速为15-28L/h;再用与上述黄豆渣醇提混合液同等重量、体积浓度为65-85%的食用乙醇洗脱,流速为40-50L/h,收集黄豆渣醇洗脱液;将黄豆渣醇洗脱液用蒸馏水稀释至醇度为30-45%,再在压力为1.2-1.75MPa的条件下,经反渗透膜过滤,收集黄豆渣醇洗脱过滤液;将黄豆渣醇洗脱过滤液在压力为10-16KPa、温度为55-70℃下浓缩至原体积的20-35%,得黄豆渣浓缩液;将黄豆渣浓缩液和上述收集的黄豆水液合并,搅匀,即得黄豆液。
4.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的黑豆粉是按以下方法制备而成:将黑豆洗净,分离成黑豆皮和黑豆肉;将黑豆肉用1-3倍重量、45-55℃的清水密封浸泡15-30h,再将经过浸泡的黑豆肉在30-45℃下经挤压机反复处理2-3次,收集滤出的黑豆肉液,再经喷雾干燥成粉末,得黑豆肉干粉;将黑豆皮干燥后粉碎成300目以上的黑豆皮粉;再将黑豆肉干粉和黑豆皮粉混合,即得黑豆粉。
5.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的山药粉是按以下方法制备而成:将山药剥去外表皮,洗净,然后,整根放入沸水中,煮至7-8成熟,捞出;将煮过的山药切成片状,与占原山药重量1-2%的蛋白酶、0.5-1.5%的纤维素酶一起投入打浆机中处理成20-60目的浆料,在25-35℃下密封处理16-24h,过滤,收集余下浆渣;将浆渣用同等重量、4-10℃的清水浸泡20-30min,过滤;将经过浸泡浆渣在60-70℃下烘干至水份≤8%,再粉碎成80目以上的山药粉。
6.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的杜仲叶粉是按以下方法制备而成:将杜仲叶洗净,投入2-4倍重量、体积浓度为70-85%的乙醇中,常温浸泡5-10h,过滤,收集杜仲叶醇提液;将杜仲叶醇提液用清水稀释至醇度为30-35%,再用浓度为5-10%的盐酸调节pH值为5-6,得杜仲叶醇提处理液;将杜仲叶醇提处理液过由硅胶:硅藻土=4-6:1的重量比例混合制成的混合柱,流速为10-18L/h,再用由乙酸乙酯与石油醚混合组成的混合溶剂洗脱,收集乙酸乙酯:石油醚=2:0.5的洗脱馏段的杜仲叶洗脱液;将杜仲叶洗脱液在压力为8-12KPa、温度为45-60℃下浓缩至原杜仲叶洗脱液体积的1/2,得杜仲叶浓缩液;将杜仲叶浓缩液用45-60℃的温水搅拌稀释2-3倍后,转移至冷库中,静放10-15h,过滤,收集杜仲叶水液;将杜仲叶水液经喷雾干燥,得杜仲叶粉。
7.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的黄芪液是按以下方法制备而成:将黄芪,洗净、晒干,切成黄芪薄片;将黄芪薄片加入到1-3倍重量、体积浓度为35-45%的食用乙醇溶液,在40-55℃下浸泡5-8h,过滤,收集黄芪醇提液;再向黄芪薄片中加入同等重量、体积浓度为60-75%的食用乙醇溶液,常温下浸泡1-3h,过滤,收集二次黄芪醇提液;将黄芪醇提液与二次黄芪醇提液合并成黄芪醇提混合液,将黄芪醇提混合液在压力为5-10KPa、温度为50-60℃下浓缩至无醇,得无醇黄芪浓缩液;将无醇黄芪浓缩液转移至压力为2-5KPa、温度为45-55℃条件下浓缩至原黄芪薄片重量的30-45%,得黄芪浓缩液;向黄芪浓缩液中加入占黄芪浓缩液重量10-25%的麦芽糖,搅匀,然后转移至0-10℃的冷库中,静放5-10h,过滤,收集黄芪液。
8.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的茶叶液是按以下方法制备而成:将茶叶洗净,加入到2-5倍重量、pH值为6.5-7的去离子水,煮沸提取20-40min,过滤,收集茶叶水提液;待茶叶水提液冷却到10℃以下时,经高速离心,收集茶叶离心液;将茶叶离心液在压力为5-10KPa、温度为60-70℃下浓缩至原体积的20-35%,得茶叶液。
9.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的鲑鱼粉是按以下方法制备而成:将鲑鱼除去内脏和鳞片,洗净,切成鲑鱼薄片,浸泡在纯食用醋中,时间为5-8min,捞出,沥干;再将经过浸泡的鲑鱼薄片用2-4倍重量的去离子水煮沸提取1-2h,过滤,收集鲑鱼水提液;再向鲑鱼水提液中加入占鲑鱼水提液重量5-10%的果糖、5-10%的麦芽糊精、0.5-1.5%的氯化钠,搅匀,经喷雾干燥,得鲑鱼粉。
10.根据权利要求1所述的茶油降脂胶囊,其特征在于所述的牡蛎液是按以下方法制备而成:将牡蛎肉去除内脏,洗净,放入纯食用醋中浸泡40-65min,捞出,在35-45℃下自然放置6-10h;再将牡蛎肉在0-10℃下经冷压榨处理,收集滤出的牡蛎液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610172237.7A CN105831733A (zh) | 2016-03-23 | 2016-03-23 | 一种茶油降脂胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610172237.7A CN105831733A (zh) | 2016-03-23 | 2016-03-23 | 一种茶油降脂胶囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105831733A true CN105831733A (zh) | 2016-08-10 |
Family
ID=56584791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610172237.7A Withdrawn CN105831733A (zh) | 2016-03-23 | 2016-03-23 | 一种茶油降脂胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105831733A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106136248A (zh) * | 2016-06-24 | 2016-11-23 | 广东工业大学 | 一种含β‑胡萝卜素的茶油软胶囊及其制备方法 |
CN106857934A (zh) * | 2017-01-19 | 2017-06-20 | 北京双娃乳业有限公司 | 一种冬瓜茶胶囊粉及制备方法 |
CN108450567A (zh) * | 2018-04-20 | 2018-08-28 | 管天球 | 一种预防高血压茶油的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102178236A (zh) * | 2011-04-28 | 2011-09-14 | 柳正良 | 一种降糖防心脑血管并发症软胶囊及其制备方法 |
CN102283386A (zh) * | 2011-08-16 | 2011-12-21 | 中国林业科学研究院亚热带林业研究所 | 一种具有降血脂功能的复方山茶油保健品及其制备方法 |
CN103060080A (zh) * | 2013-01-06 | 2013-04-24 | 湖南金浩茶油股份有限公司 | 一种降血脂茶油的制备方法 |
-
2016
- 2016-03-23 CN CN201610172237.7A patent/CN105831733A/zh not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102178236A (zh) * | 2011-04-28 | 2011-09-14 | 柳正良 | 一种降糖防心脑血管并发症软胶囊及其制备方法 |
CN102283386A (zh) * | 2011-08-16 | 2011-12-21 | 中国林业科学研究院亚热带林业研究所 | 一种具有降血脂功能的复方山茶油保健品及其制备方法 |
CN103060080A (zh) * | 2013-01-06 | 2013-04-24 | 湖南金浩茶油股份有限公司 | 一种降血脂茶油的制备方法 |
Non-Patent Citations (4)
Title |
---|
周成明: "《80种常用中草药栽培、提取、营销》", 31 January 2015 * |
孙安迪: "《超强抗病力 免疫权威的独门养生法》", 28 February 2015 * |
林禹宏: "《于仁文说降胆固醇这样吃就对了》", 30 April 2015 * |
赵国东: "《高血脂怎样吃最健康》", 31 January 2014 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106136248A (zh) * | 2016-06-24 | 2016-11-23 | 广东工业大学 | 一种含β‑胡萝卜素的茶油软胶囊及其制备方法 |
CN106857934A (zh) * | 2017-01-19 | 2017-06-20 | 北京双娃乳业有限公司 | 一种冬瓜茶胶囊粉及制备方法 |
CN108450567A (zh) * | 2018-04-20 | 2018-08-28 | 管天球 | 一种预防高血压茶油的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103540493B (zh) | 一种灵芝茶酒的配制方法 | |
CN102293292B (zh) | 滋阴养血的保健茶及其加工方法 | |
CN104544090B (zh) | 一种即食白果的制备方法 | |
CN103689333A (zh) | 一种降压消肿面粉及其制备方法 | |
CN110624050B (zh) | 一种舒冠颗粒的制备方法 | |
CN105148077A (zh) | 一种具有降血糖功效的养生粥 | |
CN105831733A (zh) | 一种茶油降脂胶囊 | |
CN105920439A (zh) | 一种含玉米须提取物的有效部位组合物及其制备方法和应用 | |
CN103417612A (zh) | 一种中药炮制的葛根饮片及其制备方法 | |
CN106635729A (zh) | 一种山楂醋的制备方法 | |
CN107596112A (zh) | 一种补肾茶配方及其制备方法 | |
CN108450567A (zh) | 一种预防高血压茶油的制备方法 | |
CN108634013A (zh) | 一种预防脑血管硬化茶油的制备方法 | |
CN108684992A (zh) | 一种能快速醒酒的植物配方的解酒饮料及其制备方法 | |
CN106729498A (zh) | 一种放化疗后食用的蛋白粉及其制备方法 | |
CN108159191B (zh) | 壮阳健肾的组合物、用途和口服液及其制备方法 | |
CN109430847A (zh) | 一种茶油软胶囊及其制备方法 | |
CN108524676A (zh) | 一种防治心脑血管病的茶剂及其制备方法 | |
CN109112031A (zh) | 一种蜂蜜养生酒及其制备方法 | |
CN106727805A (zh) | 一种三七花原液的制备方法 | |
CN107669762A (zh) | 一种辅助降血脂保健片及其制备方法 | |
CN113425788B (zh) | 一种治疗肝病的中药组合物及其制备方法与应用 | |
CN105942518A (zh) | 一种含有牡丹籽油的保健组合物及其制备方法 | |
CN108126147A (zh) | 用于调理特禀体质的中药膏方及其加工方法 | |
CN107375847A (zh) | 一种减肥药物、其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160810 |